Journal article
Second-Generation of Deuterium-Substituted Glutamate Uptake Enhancers Exhibit Superior Drug-Like Properties in Preclinical Evaluation
ACS central science, v 12(6), pp 807-823
24 Jun 2026
PMID: 42369899
Abstract
Strategic deuterium-hydrogen exchange applied to the first-in-class positive allosteric modulators (PAMs) of the glutamate transporter EAAT2/GLT-1, ( R )-AS-1 and ( R )-AS-7, yielded novel analogues with improved drug-like properties. Specifically, incorporation of deuterium into the pyrrolidine-2,5-dione ring significantly prolonged the elimination half-life and increased both plasma and brain exposure in mice. These enhancements translated into more sustained antiseizure activity and a more favorable pharmacokinetic/pharmacodynamic (PK/PD) relationship. Similar to their nondeuterated counterparts, the new deuterated analogues displayed broad-spectrum antiseizure efficacy across multiple in vivo mouse seizure models, including maximal electroshock (MES), 6 Hz (32/44 mA), acute pentylenetetrazole (PTZ), and PTZ-induced kindling. Among these compounds, d 6 -( R )-AS-7 demonstrated the most robust antiseizure effects and the most advantageous overall pharmacokinetic profile following both intraperitoneal and oral administration. Mechanistic studies revealed that d 6 -( R )-AS-7 markedly enhanced glutamate uptake in COS-7 cells expressing EAAT2 as well as in primary astrocyte cultures. Furthermore, electrophysiological recordings in acute mouse hippocampal slices, together with two-electrode voltage-clamp recordings in Xenopus laevis oocytes expressing EAAT2, confirmed increased transporter-mediated currents. Collectively, these findings identify d 6 -( R )-AS-7 as a potent EAAT2 PAM with improved pharmacokinetic properties and strong antiseizure efficacy, supporting its further development as a therapeutic candidate for epilepsy and other disorders associated with glutamate excitotoxicity.
Metrics
1 Record Views
Details
- Title
- Second-Generation of Deuterium-Substituted Glutamate Uptake Enhancers Exhibit Superior Drug-Like Properties in Preclinical Evaluation
- Creators
- Michal Abram - Jagiellonian UniversityMarcin Jakubiec - Jagiellonian UniversityMalgorzata Szafarz - Jagiellonian UniversityAnna Rapacz - Jagiellonian UniversityMagdalena Kolasa - Maj Institute of PharmacologyAgata Faron-Gorecka - Maj Institute of PharmacologySzczepan Mogilski - Jagiellonian UniversityKaliana Veros - University of UtahSimran K. Gill - Drexel UniversityAngela Di Iacovo - University of InsubriaKatarzyna Socala - Marie CurieGniewomir Latacz - Jagiellonian UniversityJoanna Karnafal - Jagiellonian UniversityKrzysztof Pociecha - Jagiellonian UniversityJustyna Kalinowska-Tluscik - Jagiellonian UniversityMelissa Barker-Haliski - University of WashingtonElzbieta Wyska - Jagiellonian UniversityAndreia C. K. Fontana - Drexel UniversityPiotr Wlaz - Marie CurieRafal M. Kaminski - Jagiellonian UniversityCristina Roseti - University of InsubriaElena Bossi - University of InsubriaKaren S. Wilcox - University of UtahKrzysztof Kaminski (Corresponding Author) - Jagiellonian University
- Publication Details
- ACS central science, v 12(6), pp 807-823
- Publisher
- ACS Publications
- Number of pages
- 17
- Grant note
- UMO-2022/45/B/NZ7/00598 / Narodowe Centrum Nauki; National Science Centre, Poland
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Pharmacology and Physiology
- Web of Science ID
- WOS:001780501300001
- Scopus ID
- 2-s2.0-105042596985
- Other Identifier
- 991022195748204721